Recent Finacing
Recent Raise
Ophthotech develops biologic therapeutics for wet and dry age-related macular degeneration, including anti‑PDGF (Fovista/E10030) combination with anti‑VEGF and anti‑C5 (ARC1905), conducting global Phase 3 programs.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors